Rize Oncology
Kelowna
About Rize Oncology
Rize Oncology develops the DNA Template-Nuclease-Tethering, or TNT™, platform that allows donor DNA templates to be conjugated or tethered to CRISPR/Cas9 and other nucleases. The platform improves the efficiency of programming and modifying genes. Rize Oncology was co-founded by Har Grover, R. Geoffrey Sargent, William J. Garner, and Daren Graham in 2018 and is headquartered in San Lorenzo, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $1.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: cnsx:GTTX
- Website: rizeoncology.com
- Phone: 510-207-2046
Industries & Categories
Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/rize-oncology-84290 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.